Neoadjuvant chemotherapy in patients with breast cancer

Abstract

Objective To analyze the effect of neoadjuvant chemotherapy in patients with breast cancer, and further to explore its mechanism in order to provide a reliable basis for its clinical application. Methods 425 cases of breast cancer patients admitted from Jan. 2010 to Jun. 2014 were the research object, and they were divided into the control group(n=322)and the observation group(n=103). The control group received operation treatment and the observation group were added with neoadjuvant chemotherapy besides routine operation treatment. Incidence of clinical efficacy and adverse reactions of the 2 groups were statistically analyzed. Changes of vascular endothelial growth factor(s-VEGF)and microvessel density(MVD)levels before and after treatment were compared between the 2 groups. VEGF-A, the positive rate of VEGF-C and estrogen receptor(ER), progesterone receptor(PR), human epidermal growth factor receptor-2(HER2), and P53 before and after treatment were compared between the 2 groups. Results The total effective rate was obviously higher in the observation group than in the control group(77.7% vs 53.7%, χ2 =18.6, P 0.05). s-VEGF and MVD had no statistical difference between the 2 groups before treatment(P>0.05)while they were significantly lower in the observation group than those in the control group after treatment(P<0.05). The positive rate of VEGF-A, VEGF-C, ER, PR, HER-2, and P53 had no statistical difference while they were obviously lower in the observation group than those in the control group(P<0.05). Conclusions NAC can help to improve the operation efficiency in patients with breast cancer, reduce s-VEGF and MVD levels and play a role in reducing the positive rate of VEGF-A, VEGF-CER, PR, HER-2 and P53. It is an effective adjuvant treatment for breast cancer with less adverse reactions, which is worthy of clinical application. Key words: Breast cancer; Neoadjuvant chemotherapy; Vascular endothelial growth factor; Immunohistochemistry